K562-r (ATCC® CRL-3344)

Organism: Homo sapiens, human  /  Tissue: bone marrow; derived from metastatic site: pleural effusion  /  Disease: chronic myeloid leukemia at blast crisis

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue bone marrow; derived from metastatic site: pleural effusion
Product Format frozen 1.0 mL
Morphology hematopoietic
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease chronic myeloid leukemia at blast crisis
Age 53
Gender female
Applications This is a clone of the parental K562 cell line which is resistant to the tyrosine kinase inhibitor imatinib mesylate, and is paired to the K562-s clone which is sensitive to imatinib.
The paired K562-s and K562-r clones are useful cell line models of sensitivity and resistance to a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia.
Storage Conditions liquid nitrogen vapor phase
Images Cell Micrograph of K562-r, ATCC CRL-3343
Derivation Erythroid-Myeloid precursor cell line derived from chronic myeloid leukemia (CML) in blast crisis.
Clinical Data female
53 years
Oncogene BCR-ABL of the e14a2 fusion transcript type
Comments Oncogenes: BCR-ABL of the e14a2 fusion transcript type
Erythroid-myeloid precursor cell line derived from chronic myeloid leukemia (CML) in blast crisis
Complete Growth Medium The complete medium for this cell line is RPMI-1640 + 10% FBS + 2 mM L-Glutamine + 1 µM Imatinib Details for preparation of 500 ml of complete media
  • Medium: 500 mL RPMI-1640 (ATCC 30-2001)
  • Serum: 56 mL FBS (ATCC 30-2020)
  • Additive: 5.6 mL L-Glutamine (200 mM, ATCC 30-2214)
  • 0.5 mL 1 mM Imatinib working stock (see below)
To prepare 1 mM Imatinib working stock, aseptically combine the following:
  • 25 mg Imatinib (Sigma catalog # CDS022173-25MG) into 45 mL Culture grade water (Hyclone catalog # SH30529
    Note: supplement Imatinib at each reseed rather than including in culture medium bottle. The shelf life for Imatinib in culture medium is unknown, so do not use a prepared culture medium bottle for more than 30 days. Additionally, if cell growth appears to slow during cell line expansion, prepare a new bottle of fresh medium.
Subculturing
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2.5 to 3.5 X 105 cells/mL and maintain between 2 X 105 and 1 X 106 cells/mL.

Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density).
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
Cells per Vial 6 to 8 X 106
Volume 1.0 mL
STR Profile
Amelogenin: X
CSF1PO: 9,10
D13S317: 8
D16S539: 11,12
D5S818: 11,12
D7S820: 9,11
TH01: 9.3
TPOX: 8,9
vWA: 16
Sterility Tests Bacteria and Yeast: No growth
Mycoplasma: No growth
Population Doubling Time approximately 24-30 hours
Name of Depositor J Vaz deMelo, University of Adelaide, Australia
Year of Origin 1999
References

Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321-334, 1975. PubMed: 163658

Mahon FX, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96(3): 1070-1079, 2000 PubMed: 10910924

Lozzio CC, Lozzio BB. Cytotoxicity of a factor isolated from human spleen. J Natl Canc Inst 50(2): 535-538, 1973. PubMed: 4512889

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321-334, 1975. PubMed: 163658

Mahon FX, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96(3): 1070-1079, 2000 PubMed: 10910924

Lozzio CC, Lozzio BB. Cytotoxicity of a factor isolated from human spleen. J Natl Canc Inst 50(2): 535-538, 1973. PubMed: 4512889